Alvine Pharmaceuticals

Alvine Pharmaceuticals is a privately held biopharmaceutical company established in 2005, with a focus on providing innovative treatments for autoimmune and gastrointestinal diseases. The company's flagship product, ALV003, is a groundbreaking combination protease intended to break down gluten, targeting patients with celiac disease. With a slogan of "Pioneering solutions for autoimmune and gastrointestinal health," Alvine Pharmaceuticals demonstrates a strong commitment to developing cutting-edge technologies in the biotechnology, health and wellness, and pharmaceutical industries. The company successfully secured a $6.01M Debt Financing investment on 03 January 2013, reflecting the confidence of investors in its potential to address unmet medical needs. This investment further underscores the company's promising trajectory in providing solutions for prevalent health challenges.